News | October 14, 2024
Zydus and ICMR initiate a Phase 2 trial of Desidustat in patients with Sickle Cell Disease
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The company will also share results in two additional posters for deuruxolitinib
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Launch of 20 new medicines expected by 2030
Subscribe To Our Newsletter & Stay Updated
